{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,7]],"date-time":"2025-05-07T23:21:33Z","timestamp":1746660093338,"version":"3.37.3"},"reference-count":80,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2023,5,25]],"date-time":"2023-05-25T00:00:00Z","timestamp":1684972800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,5,25]],"date-time":"2023-05-25T00:00:00Z","timestamp":1684972800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Intern Emerg Med"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1007\/s11739-023-03306-8","type":"journal-article","created":{"date-parts":[[2023,5,25]],"date-time":"2023-05-25T11:02:25Z","timestamp":1685012545000},"page":"1619-1634","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Ambulatory cancer patients: who should definitely receive antithrombotic prophylaxis and who should never receive"],"prefix":"10.1007","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4185-979X","authenticated-orcid":false,"given":"Melina","family":"Verso","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andres","family":"Mu\u00f1oz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean M.","family":"Connors","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,5,25]]},"reference":[{"key":"3306_CR1","doi-asserted-by":"publisher","first-page":"1712","DOI":"10.1182\/blood-2013-04-460121","volume":"122","author":"JF Timp","year":"2013","unstructured":"Timp JF, Breakkan SK, Versteeg HH, Cannegieter SC (2013) Epidemiology of cancer-associated venous thrombosis. Blood 122:1712\u20131723. https:\/\/doi.org\/10.1182\/blood-2013-04-460121","journal-title":"Blood"},{"issue":"21","key":"3306_CR2","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1182\/blood.V118.21.674.674","volume":"118","author":"AA Khorana","year":"2011","unstructured":"Khorana AA, Dalal M, Tangirala K, Miao R (2011) Higher incidence of venous thromboembolism in the outpatient versus the inpatient setting among US cancer patients. Blood 118(21):674","journal-title":"Blood"},{"issue":"4","key":"3306_CR3","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1001\/archinte.166.4.458","volume":"166","author":"HK Chew","year":"2006","unstructured":"Chew HK, Wun T, Harvey D, Zhou H, White RH (2006) Incidence of venous thromboembolism and its effect on survival among patients with common cancers. Arch Intern Med 166(4):458\u2013464. https:\/\/doi.org\/10.1001\/archinte.166.4.458","journal-title":"Arch Intern Med"},{"key":"3306_CR4","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1007\/s11739-013-0985-z","volume":"9","author":"G Agnelli","year":"2014","unstructured":"Agnelli G, Verso M, Mandal\u00e0 M, Gallus S, Cimminiello C, Apolone G, Di Minno G, Maiello E, Prandoni P, Santoro A, Crin\u00f2 L, Labianca R (2014) A prospective study on survival in cancer patients with and without venous thromboembolism. Intern Emerg Med 9:559\u2013567. https:\/\/doi.org\/10.1007\/s11739-013-0985-z","journal-title":"Intern Emerg Med"},{"issue":"3","key":"3306_CR5","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1016\/j.chest.2020.05.559","volume":"158","author":"LK Moores","year":"2020","unstructured":"Moores LK, Tritschler T, Brosnahan S, Carrier M, Collen JF, Doerschug K, Holley AB, Jimenez D, Le Gal G, Rali P, Wells P (2020) Prevention, diagnosis, and treatment of VTE in patients with coronavirus disease 2019: CHEST guideline and expert panel report. Chest 158(3):1143\u20131163. https:\/\/doi.org\/10.1016\/j.chest.2020.05.559","journal-title":"Chest"},{"issue":"4","key":"3306_CR6","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1182\/bloodadvances.2020003442","volume":"5","author":"GH Lyman","year":"2021","unstructured":"Lyman GH, Carrier M, Ay C, Di Nisio M, Hicks LK, Khorana AA, Leavitt AD, Lee AYY, Macbeth F, Morgan RL, Noble S, Sexton EA, Stenehjem D, Wiercioch W, Kahale LA, Alonso-Coello P (2021) American society of hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer. Blood Adv 5(4):927\u2013974. https:\/\/doi.org\/10.1182\/bloodadvances.2020003442","journal-title":"Blood Adv"},{"issue":"7","key":"3306_CR7","doi-asserted-by":"publisher","first-page":"e334","DOI":"10.1016\/S1470-2045(22)00160-7","volume":"23","author":"D Farge","year":"2022","unstructured":"Farge D, Frere C, Connors JM, Khorana AA, Kakkar A, Ay C, Mu\u00f1oz A, Brenner B, Prata PH, Brilhante D, Antic D, Casais P, Guillermo Esposito MC, Ikezoe T, Abutalib SA, Meillon-Garc\u00eda LA, Bounameaux H, Pabinger I, Douketis J, International Initiative on Thrombosis and Cancer (ITAC) advisory panel (2022) 2022 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer, including patients with COVID-19. Lancet Oncol 23(7):e334\u2013e347. https:\/\/doi.org\/10.1016\/S1470-2045(22)00160-7","journal-title":"Lancet Oncol"},{"key":"3306_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.6004\/jnccn.2021.7108","volume":"21","author":"A Elshoury","year":"2022","unstructured":"Elshoury A, Schaefer JK, Lim MY, Skalla DP, Streiff MB (2022) Update on guidelines for the prevention of cancer-associated thrombosis. J Natl Compr Canc Netw 21:1\u20138. https:\/\/doi.org\/10.6004\/jnccn.2021.7108","journal-title":"J Natl Compr Canc Netw"},{"key":"3306_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.12.014","author":"A Falanga","year":"2023","unstructured":"Falanga A, Ay C, Di Nisio M, Gerotziafas G, Langer F, Lecumberri R, Mandala M, Maraveyas A, Pabinger I, Jara-Palomares L, Sinn M, Syrigos K, Young A, Jordan K, ESMO Guidelines Committee (2023) Venous thromboembolism in cancer patients: ESMO clinical practice guideline. Ann Oncol. https:\/\/doi.org\/10.1016\/j.annonc.2022.12.014","journal-title":"Ann Oncol"},{"key":"3306_CR10","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.00294","author":"NS Key","year":"2023","unstructured":"Key NS, Khorana AA, Kuderer NM, Bohlke K, Lee AYY, Arcelus JI, Wong SL, Balaban EP, Flowers CR, Gates LE, Kakkar AK, Tempero MA, Gupta S, Lyman GH, Falanga A (2023) Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO guideline update. J Clin Oncol. https:\/\/doi.org\/10.1200\/JCO.23.00294","journal-title":"J Clin Oncol"},{"issue":"1","key":"3306_CR11","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1160\/TH15-08-0686","volume":"117","author":"AT Cohen","year":"2017","unstructured":"Cohen AT, Katholing A, Rietbrock S, Bamber L, Martinez C (2017) Epidemiology of first and recurrent venous thromboembolism in patients with active cancer. A population-based cohort study. Thromb Haemost 117(1):57\u201365. https:\/\/doi.org\/10.1160\/TH15-08-0686","journal-title":"Thromb Haemost"},{"issue":"4","key":"3306_CR12","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1111\/j.1538-7836.2008.02908.x","volume":"6","author":"HK Chew","year":"2008","unstructured":"Chew HK, Davies AM, Wun T, Harvey D, Zhou H, White RH (2008) The incidence of venous thromboembolism among patients with primary lung cancer. J Thromb Haemost 6(4):601\u2013608. https:\/\/doi.org\/10.1111\/j.1538-7836.2008.02908.x","journal-title":"J Thromb Haemost"},{"issue":"3","key":"3306_CR13","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1111\/j.1538-7836.2006.01804.x","volume":"4","author":"JW Blom","year":"2006","unstructured":"Blom JW, Vanderschoot JP, Oostindi\u00ebr MJ, Osanto S, van der Meer FJ, Rosendaal FR (2006) Incidence of venous thrombosis in a large cohort of 66,329 cancer patients: results of a record linkage study. J Thromb Haemost 4(3):529\u2013535. https:\/\/doi.org\/10.1111\/j.1538-7836.2006.01804.x","journal-title":"J Thromb Haemost"},{"issue":"5","key":"3306_CR14","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1053\/j.gastro.2019.12.009","volume":"158","author":"C Frere","year":"2020","unstructured":"Frere C, Bournet B, Gourgou S, Fraisse J, Canivet C, Connors JM, Buscail L, Farge D, BACAP Consortium (2020) Incidence of venous thromboembolism in patients with newly diagnosed pancreatic cancer and factors associated with outcomes. Gastroenterology 158(5):1346-1358.e4. https:\/\/doi.org\/10.1053\/j.gastro.2019.12.009","journal-title":"Gastroenterology"},{"key":"3306_CR15","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.ejca.2022.01.023","volume":"165","author":"M Verso","year":"2022","unstructured":"Verso M, Agnelli G, Munoz A, Connors JM, Sanchez O, Huisman M, Brenner B, Gussoni G, Cohen AT, Becattini C (2022) Recurrent venous thromboembolism and major bleeding in patients with localized, locally advanced or metastatic cancer: an analysis of the Caravaggio study. Eur J Cancer 165:136\u2013145. https:\/\/doi.org\/10.1016\/j.ejca.2022.01.023","journal-title":"Eur J Cancer"},{"issue":"7","key":"3306_CR16","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1111\/jth.14149","volume":"16","author":"M Di Nisio","year":"2018","unstructured":"Di Nisio M, Candeloro M, Rutjes AWS, Porreca E (2018) Venous thromboembolism in cancer patients receiving neoadjuvant chemotherapy: a systematic review and meta-analysis. J Thromb Haemost 16(7):1336\u20131346. https:\/\/doi.org\/10.1111\/jth.14149","journal-title":"J Thromb Haemost"},{"issue":"Suppl C","key":"3306_CR17","doi-asserted-by":"publisher","first-page":"C2","DOI":"10.1093\/eurheartj\/suaa004","volume":"22","author":"AJ Mu\u00f1oz Mart\u00edn","year":"2020","unstructured":"Mu\u00f1oz Mart\u00edn AJ, Ram\u00edrez SP, Mor\u00e1n LO, Zamorano MR, Ben\u00e9itez MCV, Salcedo IA, Escobar IG, Fern\u00e1ndez JMS (2020) Pharmacological cancer treatment and venous thromboembolism risk. Eur Heart J Suppl 22(Suppl C):C2\u2013C14. https:\/\/doi.org\/10.1093\/eurheartj\/suaa004","journal-title":"Eur Heart J Suppl"},{"issue":"14","key":"3306_CR18","doi-asserted-by":"publisher","first-page":"1959","DOI":"10.1182\/blood.2020007338","volume":"137","author":"FI Mulder","year":"2021","unstructured":"Mulder FI, Horv\u00e1th-Puh\u00f3 E, van Es N, van Laarhoven HWM, Pedersen L, Moik F, Ay C, B\u00fcller HR, S\u00f8rensen HT (2021) Venous thromboembolism in cancer patients: a population-based cohort study. Blood 137(14):1959\u20131969. https:\/\/doi.org\/10.1182\/blood.2020007338","journal-title":"Blood"},{"issue":"7","key":"3306_CR19","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1111\/j.1538-7836.2010.03901.x","volume":"8","author":"M Verso","year":"2010","unstructured":"Verso M, Gussoni G, Agnelli G (2010) Prevention of venous thromboembolism in patients with advanced lung cancer receiving chemotherapy: a combined analysis of the PROTECHT and TOPIC-2 studies. J Thromb Haemost 8(7):1649\u20131651. https:\/\/doi.org\/10.1111\/j.1538-7836.2010.03901.x","journal-title":"J Thromb Haemost"},{"issue":"2","key":"3306_CR20","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1111\/bju.14685","volume":"124","author":"JD Ramos","year":"2019","unstructured":"Ramos JD, Holt SK, Schade GR, Galsky MD, Wright JL, Gore JL, Yu EY (2019) Chemotherapy regimen is associated with venous thromboembolism risk in patients with urothelial tract cancer. BJU Int 124(2):290\u2013296. https:\/\/doi.org\/10.1111\/bju.14685","journal-title":"BJU Int"},{"issue":"12","key":"3306_CR21","doi-asserted-by":"publisher","first-page":"2932","DOI":"10.1093\/annonc\/mdx514","volume":"28","author":"D Arnold","year":"2017","unstructured":"Arnold D, Fuchs CS, Tabernero J, Ohtsu A, Zhu AX, Garon EB, Mackey JR, Paz-Ares L, Baron AD, Okusaka T, Yoshino T, Yoon HH, Das M, Ferry D, Zhang Y, Lin Y, Binder P, Sashegyi A, Chau I (2017) Meta-analysis of individual patient safety data from six randomized, placebo-controlled trials with the antiangiogenic VEGFR2-binding monoclonal antibody ramucirumab. Ann Oncol 28(12):2932\u20132942. https:\/\/doi.org\/10.1093\/annonc\/mdx514","journal-title":"Ann Oncol"},{"issue":"10","key":"3306_CR22","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1055\/a-1816-8347","volume":"122","author":"A Carmona-Bayonas","year":"2022","unstructured":"Carmona-Bayonas A, Verso M, C\u00e1novas MS, P\u00e9rez JR, de Herreros MG, De Prado PM, P\u00e9rez IF, Verduguez TQ, Portero BO, Olmos VP, G\u00f3mez D, Ortega L, Moyano MS, Brozos EM, Biosca M, Rebollo MA, Sanchez LT, P\u00e9rez CH, Cumplidour\u00f3n JD, Lago NM, P\u00e9rez EG, Langa JM, Segura PP, de Castro EM, Jimenez-Fonseca P, Agnelli G, Mu\u00f1oz A (2022) Do antiangiogenics promote clot instability? Data from the teseo prospective registry and Caravaggio clinical trial. Thromb Haemost 122(10):1653\u20131661. https:\/\/doi.org\/10.1055\/a-1816-8347","journal-title":"Thromb Haemost"},{"issue":"5","key":"3306_CR23","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1111\/ejh.13590","volume":"106","author":"MT West","year":"2021","unstructured":"West MT, Smith CE, Kaempf A, Kohs TCL, Amirsoltani R, Ribkoff J, Choung JL, Palumbo A, Mitri Z, Shatzel JJ (2021) CDK 4\/6 inhibitors are associated with a high incidence of thrombotic events in women with breast cancer in real-world practice. Eur J Haematol 106(5):634\u2013642. https:\/\/doi.org\/10.1111\/ejh.13590","journal-title":"Eur J Haematol"},{"issue":"2","key":"3306_CR24","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1007\/s10549-020-05783-3","volume":"183","author":"KZ Thein","year":"2020","unstructured":"Thein KZ, Htut TW, Ball S, Swarup S, Sultan A, Oo TH (2020) Venous thromboembolism risk in patients with hormone receptor-positive HER2-negative metastatic breast cancer treated with combined CDK 4\/6 inhibitors plus endocrine therapy versus endocrine therapy alone: a systematic review and meta-analysis of randomized controlled trials. Breast Cancer Res Treat 183(2):479\u2013487. https:\/\/doi.org\/10.1007\/s10549-020-05783-3","journal-title":"Breast Cancer Res Treat"},{"issue":"12","key":"3306_CR25","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.1182\/blood.2020007878","volume":"137","author":"F Moik","year":"2021","unstructured":"Moik F, Chan WE, Wiedemann S, Hoeller C, Tuchmann F, Aretin MB, Fuereder T, Z\u00f6chbauer-M\u00fcller S, Preusser M, Pabinger I, Ay C (2021) Incidence, risk factors, and outcomes of venous and arterial thromboembolism in immune checkpoint inhibitor therapy. Blood 137(12):1669\u20131678. https:\/\/doi.org\/10.1182\/blood.2020007878","journal-title":"Blood"},{"issue":"3","key":"3306_CR26","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1097\/COC.0000000000000981","volume":"46","author":"B Dutra","year":"2023","unstructured":"Dutra B, Garcia-Rodriguez V, Garcia R, Szafron D, Abraham F, Khurana S, Lockhart J, Amin R, Wang Y, Thomas A (2023) Characteristics and outcomes of cancer patients with venous thromboembolic events after treatment with immune checkpoint inhibitors. Am J Clin Oncol 46(3):94\u2013100. https:\/\/doi.org\/10.1097\/COC.0000000000000981","journal-title":"Am J Clin Oncol"},{"key":"3306_CR27","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.thromres.2021.10.014","volume":"208","author":"H Hill","year":"2021","unstructured":"Hill H, Robinson M, Lu L, Slaughter D, Amin A, Mileham K, Patel JN (2021) Venous thromboembolism incidence and risk factors in non-small cell lung cancer patients receiving first-line systemic therapy. Thromb Res 208:71\u201378. https:\/\/doi.org\/10.1016\/j.thromres.2021.10.014","journal-title":"Thromb Res"},{"key":"3306_CR28","doi-asserted-by":"publisher","first-page":"k3845","DOI":"10.1136\/bmj.k3845","volume":"363","author":"A Matthews","year":"2018","unstructured":"Matthews A, Stanway S, Farmer RE, Strongman H, Thomas S, Lyon AR, Smeeth L, Bhaskaran K (2018) Long term adjuvant endocrine therapy and risk of cardiovascular disease in female breast cancer survivors: systematic review. BMJ 363:k3845. https:\/\/doi.org\/10.1136\/bmj.k3845","journal-title":"BMJ"},{"issue":"6","key":"3306_CR29","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1016\/j.annonc.2022.03.006","volume":"33","author":"HS Hugo","year":"2022","unstructured":"Hugo HS, O\u2019Shaughnessy J, Boyle F, Toi M, Broom R, Blancas I, Gumus M, Yamashita T, Im YH, Rastogi P, Zagouri F, Song C, Campone M, San Antonio B, Shahir A, Hulstijn M, Brown J, Zimmermann A, Wei R, Johnston SRD, Reinisch M, Tolaney SM, monarch E Committee Members (2022) Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: safety and patient-reported outcomes from the monarchE study. Ann Oncol 33(6):616\u2013627. https:\/\/doi.org\/10.1016\/j.annonc.2022.03.006","journal-title":"Ann Oncol"},{"issue":"23","key":"3306_CR30","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1093\/jnci\/djp387","volume":"101","author":"DL Hershman","year":"2009","unstructured":"Hershman DL, Buono DL, Malin J, McBride R, Tsai WY, Neugut AI (2009) Patterns of use and risks associated with erythropoiesis-stimulating agents among Medicare patients with cancer. J Natl Cancer Inst 101(23):1633\u20131641. https:\/\/doi.org\/10.1093\/jnci\/djp387. (Epub 2009 Nov 10)","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"3306_CR31","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1007\/s13277-013-1084-5","volume":"35","author":"S Gao","year":"2014","unstructured":"Gao S, Ma JJ, Lu C (2014) Venous thromboembolism risk and erythropoiesis-stimulating agents for the treatment of cancer-associated anemia: a meta-analysis. Tumour Biol 35(1):603\u2013613. https:\/\/doi.org\/10.1007\/s13277-013-1084-5","journal-title":"Tumour Biol"},{"issue":"12","key":"3306_CR32","doi-asserted-by":"publisher","first-page":"008500","DOI":"10.1002\/14651858.CD008500.pub5","volume":"12","author":"AW Rutjes","year":"2020","unstructured":"Rutjes AW, Porreca E, Candeloro M, Valeriani E, Di Nisio M (2020) Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy. Cochrane Database Syst Rev 12(12):008500. https:\/\/doi.org\/10.1002\/14651858.CD008500.pub5","journal-title":"Cochrane Database Syst Rev"},{"key":"3306_CR33","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1016\/S1470-2045(09)70232-3","volume":"10","author":"G Agnelli","year":"2009","unstructured":"Agnelli G, Gussoni G, Bianchini C, Verso M, Mandal\u00e0 M, Cavanna L, Barni S, Labianca R, Buzzi F, Scambia G, Passalacqua R, Ricci S, Gasparini G, Lorusso V, Bonizzoni E, Tonato M, PROTECHT Investigators (2009) Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double- blind study. Lancet Oncol 10:943\u2013949. https:\/\/doi.org\/10.1016\/S1470-2045(09)70232-3","journal-title":"Lancet Oncol"},{"key":"3306_CR34","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1056\/NEJMoa1108898","volume":"366","author":"G Agnelli","year":"2012","unstructured":"Agnelli G, George DJ, Kakkar AK, Fisher W, Lassen MR, Mismetti P, Mouret P, Chaudhari U, Lawson F, Turpie AG, SAVE-ONCO Investigators (2012) Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer. N Engl J Med 366:601\u2013609. https:\/\/doi.org\/10.1056\/NEJMoa1108898","journal-title":"N Engl J Med"},{"issue":"10","key":"3306_CR35","doi-asserted-by":"publisher","first-page":"4902","DOI":"10.1182\/blood-2007-10-116327","volume":"111","author":"AA Khorana","year":"2008","unstructured":"Khorana AA, Kuderer NM, Culakova E, Lyman GH, Francis CW (2008) Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood 111(10):4902\u20134907. https:\/\/doi.org\/10.1182\/blood-2007-10-116327","journal-title":"Blood"},{"key":"3306_CR36","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.3324\/haematol.2018.209114","volume":"104","author":"FI Mulder","year":"2019","unstructured":"Mulder FI, Candeloro M, Kamphuisen PW, Di Nisio M, Bossuyt PM, Guman N, Smit K, B\u00fcller HR, van Nick ES, CAT-prediction collaborators (2019) The Khorana score for prediction of venous thromboembolism in cancer patients: a systematic review and meta-analysis. Hematologica 104:1277\u20131287. https:\/\/doi.org\/10.3324\/haematol.2018.209114","journal-title":"Hematologica"},{"issue":"10","key":"3306_CR37","doi-asserted-by":"publisher","first-page":"2967","DOI":"10.1182\/bloodadvances.2021006484","volume":"6","author":"TF Overvad","year":"2022","unstructured":"Overvad TF, Ording AG, Nielsen PB, Skj\u00f8th F, Albertsen IE, Noble S, Vistisen AK, Gade IL, Severinsen MT, Piazza G, Larsen TB (2022) Validation of the Khorana score for predicting venous thromboembolism in 40 218 patients with cancer initiating chemotherapy. Blood Adv 6(10):2967\u20132976. https:\/\/doi.org\/10.1182\/bloodadvances.2021006484","journal-title":"Blood Adv"},{"issue":"3","key":"3306_CR38","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1007\/s11739-012-0784-y","volume":"7","author":"M Verso","year":"2012","unstructured":"Verso M, Agnelli G, Barni S, Gasparini G, LaBianca R (2012) A modified Khorana risk assessment score for venous thromboembolism in cancer patients receiving chemotherapy: the Protecht score. Intern Emerg Med 7(3):291\u2013292. https:\/\/doi.org\/10.1007\/s11739-012-0784-y","journal-title":"Intern Emerg Med"},{"issue":"18","key":"3306_CR39","doi-asserted-by":"publisher","first-page":"2028","DOI":"10.1200\/JCO.2014.55.1481","volume":"33","author":"U Pelzer","year":"2015","unstructured":"Pelzer U, Opitz B, Deutschinoff G, Stauch M, Reitzig PC, Hahnfeld S, M\u00fcller L, Grunewald M, Stieler JM, Sinn M, Denecke T, Bischoff S, Oettle H, D\u00f6rken B, Riess H (2015) Efficacy of prophylactic low-molecular weight heparin for ambulatory patients with advanced pancreatic cancer: outcomes from the CONKO-004 Trial. J Clin Oncol 33(18):2028\u20132034. https:\/\/doi.org\/10.1200\/JCO.2014.55.1481","journal-title":"J Clin Oncol"},{"issue":"10","key":"3306_CR40","doi-asserted-by":"publisher","first-page":"1222","DOI":"10.1634\/theoncologist.2016-0414","volume":"22","author":"GT Gerotziafas","year":"2017","unstructured":"Gerotziafas GT, Taher A, Abdel-Razeq H, AboElnazar E, Spyropoulos AC, El Shemmari S, Larsen AK, Elalamy I, COMPASS\u2013CAT Working Group (2017) A predictive score for thrombosis associated with breast, colorectal, lung, or ovarian cancer: the prospective COMPASS-cancer-associated thrombosis study. Oncologist 22(10):1222\u20131231. https:\/\/doi.org\/10.1634\/theoncologist.2016-0414","journal-title":"Oncologist"},{"issue":"5","key":"3306_CR41","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1634\/theoncologist.2016-0246","volume":"22","author":"CA Cella","year":"2017","unstructured":"Cella CA, Di Minno G, Carlomagno C, Arcopinto M, Cerbone AM, Matano E, Tufano A, Lordick F, De Simone B, Muehlberg KS, Bruzzese D, Attademo L, Arturo C, Sodano M, Moretto R, La Fata E, De Placido S (2017) Preventing venous thromboembolism in ambulatory cancer patients: the ONKOTEV study. Oncologist 22(5):601\u2013608. https:\/\/doi.org\/10.1634\/theoncologist.2016-0246","journal-title":"Oncologist"},{"issue":"8","key":"3306_CR42","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1038\/s41416-018-0027-8","volume":"118","author":"AJ Mu\u00f1oz Mart\u00edn","year":"2018","unstructured":"Mu\u00f1oz Mart\u00edn AJ, Ortega I, Font C, Pach\u00f3n V, Castell\u00f3n V, Mart\u00ednez-Mar\u00edn V, Salgado M, Mart\u00ednez E, Calzas J, Rup\u00e9rez A, Souto JC, Mart\u00edn M, Salas E, Soria JM (2018) Multivariable clinical-genetic risk model for predicting venous thromboembolic events in patients with cancer. Br J Cancer 118(8):1056\u20131061. https:\/\/doi.org\/10.1038\/s41416-018-0027-8","journal-title":"Br J Cancer"},{"issue":"7","key":"3306_CR43","doi-asserted-by":"publisher","first-page":"e289","DOI":"10.1016\/S2352-3026(18)30063-2","volume":"5","author":"I Pabinger","year":"2018","unstructured":"Pabinger I, van Es N, Heinze G, Posch F, Riedl J, Reitter EM, Di Nisio M, Cesarman-Maus G, Kraaijpoel N, Zielinski CC, B\u00fcller HR, Ay C (2018) A clinical prediction model for cancer-associated venous thromboembolism: a development and validation study in two independent prospective cohorts. Lancet Haematol 5(7):e289\u2013e298. https:\/\/doi.org\/10.1016\/S2352-3026(18)30063-2","journal-title":"Lancet Haematol"},{"issue":"12","key":"3306_CR44","doi-asserted-by":"publisher","first-page":"2152","DOI":"10.1111\/jth.14614","volume":"17","author":"DR Douce","year":"2019","unstructured":"Douce DR, Holmes CE, Cushman M, MacLean CD, Ades S, Zakai NA (2019) Risk factors for cancer-associated venous thromboembolism: The venous thromboembolism prevention in the ambulatory cancer clinic (VTE-PACC) study. J Thromb Haemost 17(12):2152\u20132159. https:\/\/doi.org\/10.1111\/jth.14614","journal-title":"J Thromb Haemost"},{"issue":"1","key":"3306_CR45","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1007\/s11239-019-01845-6","volume":"48","author":"M Di Nisio","year":"2019","unstructured":"Di Nisio M, van Es N, Rotunno L, Anzoletti N, Falcone L, De Tursi M, Natoli C, Tinari N, Cavallo I, Valeriani E, Candeloro M, Guglielmi MD, Rutjes AWS, Porreca E (2019) Long-term performance of risk scores for venous thromboembolism in ambulatory cancer patients. J Thromb Thrombolysis 48(1):125\u2013133. https:\/\/doi.org\/10.1007\/s11239-019-01845-6","journal-title":"J Thromb Thrombolysis"},{"issue":"9","key":"3306_CR46","doi-asserted-by":"publisher","first-page":"1494","DOI":"10.3324\/haematol.2017.169060","volume":"102","author":"N van Es","year":"2017","unstructured":"van Es N, Di Nisio M, Cesarman G, Kleinjan A, Otten HM, Mah\u00e9 I, Wilts IT, Twint DC, Porreca E, Arrieta O, St\u00e9panian A, Smit K, De Tursi M, Bleker SM, Bossuyt PM, Nieuwland R, Kamphuisen PW, B\u00fcller HR (2017) Comparison of risk prediction scores for venous thromboembolism in cancer patients: a prospective cohort study. Haematologica 102(9):1494\u20131501. https:\/\/doi.org\/10.3324\/haematol.2017.169060","journal-title":"Haematologica"},{"key":"3306_CR47","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1056\/NEJMoa1814630","volume":"380","author":"AA Khorana","year":"2019","unstructured":"Khorana AA, Soff GA, Kakkar AK, Vadhan-Raj S, Riess H, Wun T, Streiff MB, Garcia DA, Liebman HA, Belani CP, O\u2019Reilly EM, Patel JN, Yimer HA, Wildgoose P, Burton P, Vijapurkar U, Kaul S, Eikelboom J, McBane R, Bauer KA, Kuderer NM, Lyman GH (2019) Rivaroxaban for thromboprophylaxis in high-risk ambulatory patients with cancer. N Engl J Med 380:720\u2013728. https:\/\/doi.org\/10.1056\/NEJMoa1814630","journal-title":"N Engl J Med"},{"key":"3306_CR48","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1814468","volume":"380","author":"M Carrier","year":"2019","unstructured":"Carrier M, Abou-Nassar K, Mallick R, Tagalakis V, Shivakumar S, Schattner A, Kuruvilla P, Hill D, Spadafora S, Marquis K, Trinkaus M, Tomiak A, Lee AYY, Gross PL, Lazo-Langner A, El-Maraghi R, Goss G, Le Gal G, Stewart D, Ramsay T, Rodger M, Witham D, Wells PS, A.V.E.R.T. Investigators (2019) Apixaban to prevent venous thromboembolism in patients with cancer. N Engl J Med 380:711\u2013719. https:\/\/doi.org\/10.1056\/NEJMoa1814468","journal-title":"N Engl J Med"},{"issue":"8","key":"3306_CR49","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1056\/NEJMe1816060","volume":"380","author":"G Agnelli","year":"2019","unstructured":"Agnelli G (2019) Direct oral anticoagulants for thromboprophylaxis in ambulatory patients with cancer. N Engl J Med 380(8):781\u2013783. https:\/\/doi.org\/10.1056\/NEJMe1816060","journal-title":"N Engl J Med"},{"issue":"5","key":"3306_CR50","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1055\/s-0041-1735251","volume":"122","author":"MA de Winter","year":"2022","unstructured":"de Winter MA, Dorresteijn JAN, Ageno W, Ay C, Beyer-Westendorf J, Coppens M, Klok FA, Moustafa F, Riva N, Ruiz Artacho PC, Vanassche T, Nijkeuter M (2022) Estimating bleeding risk in patients with cancer-associated thrombosis: evaluation of existing risk scores and development of a new risk score. Thromb Haemost 122(5):818\u2013829. https:\/\/doi.org\/10.1055\/s-0041-1735251","journal-title":"Thromb Haemost"},{"issue":"8","key":"3306_CR51","doi-asserted-by":"publisher","first-page":"2028","DOI":"10.3390\/cancers12082028","volume":"12","author":"C Frere","year":"2020","unstructured":"Frere C, Crichi B, Bournet B, Canivet C, Abdallah NA, Buscail L, Farge D (2020) Primary thromboprophylaxis in ambulatory pancreatic cancer patients receiving chemotherapy: a systematic review and meta-analysis of randomized controlled trials. Cancers (Basel) 12(8):2028. https:\/\/doi.org\/10.3390\/cancers12082028","journal-title":"Cancers (Basel)"},{"issue":"9","key":"3306_CR52","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1016\/j.ejca.2011.10.017","volume":"48","author":"A Maraveyas","year":"2012","unstructured":"Maraveyas A, Waters J, Roy R, Fyfe D, Propper D, Lofts F, Sgouros J, Gardiner E, Wedgwood K, Ettelaie C, Bozas G (2012) Gemcitabine versus gemcitabine plus dalteparin thromboprophylaxis in pancreatic cancer. Eur J Cancer 48(9):1283\u20131292. https:\/\/doi.org\/10.1016\/j.ejca.2011.10.017","journal-title":"Eur J Cancer"},{"key":"3306_CR53","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.thromres.2021.03.013","volume":"202","author":"D Ladha","year":"2021","unstructured":"Ladha D, Mallick R, Wang TF, Caiano L, Wells PS, Carrier M (2021) Efficacy and safety of apixaban for primary prevention in gastrointestinal cancers: a post-hoc analysis of the AVERT trial. Thromb Res 202:151\u2013154. https:\/\/doi.org\/10.1016\/j.thromres.2021.03.013","journal-title":"Thromb Res"},{"issue":"3","key":"3306_CR54","doi-asserted-by":"publisher","first-page":"838","DOI":"10.3324\/haematol.2019.221424","volume":"105","author":"C Becattini","year":"2020","unstructured":"Becattini C, Verso M, Mu\u0148oz A, Agnelli G (2020) Updated meta-analysis on prevention of venous thromboembolism in ambulatory cancer patients. Haematologica 105(3):838\u2013848. https:\/\/doi.org\/10.3324\/haematol.2019.221424","journal-title":"Haematologica"},{"issue":"2","key":"3306_CR55","doi-asserted-by":"publisher","first-page":"e230010","DOI":"10.1001\/jamanetworkopen.2023.0010","volume":"6","author":"CA Cella","year":"2023","unstructured":"Cella CA, Knoedler M, Hall M et al (2023) Validation of the ONKOTEV risk prediction model for venous thromboembolism in outpatients with cancer. JAMA Netw Open 6(2):e230010. https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.0010","journal-title":"JAMA Netw Open"},{"issue":"3","key":"3306_CR56","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.lungcan.2012.09.007","volume":"78","author":"GC Connolly","year":"2012","unstructured":"Connolly GC, Dalal M, Lin J, Khorana AA (2012) Incidence and predictors of venous thromboembolism (VTE) among ambulatory patients with lung cancer. Lung Cancer 78(3):253\u2013258. https:\/\/doi.org\/10.1016\/j.lungcan.2012.09.007","journal-title":"Lung Cancer"},{"issue":"5","key":"3306_CR57","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1016\/j.thromres.2015.09.006","volume":"136","author":"M Verso","year":"2015","unstructured":"Verso M, Chiari R, Mosca S, Franco L, Fischer M, Paglialunga L, Bennati C, Scialpi M, Agnelli G (2015) Incidence of Ct scan-detected pulmonary embolism in patients with oncogene-addicted, advanced lung adenocarcinoma. Thromb Res 136(5):924\u2013927. https:\/\/doi.org\/10.1016\/j.thromres.2015.09.006","journal-title":"Thromb Res"},{"key":"3306_CR58","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.ejca.2020.10.002","volume":"141","author":"N Munoz-Unceta","year":"2020","unstructured":"Munoz-Unceta N, Zugazagoitia J, Manzano A, Jim\u00e9nez-Aguilar E, Olmedo ME, Cacho JD, Oliveira J, D\u00f3mine M, Ortega-Mor\u00e1n L, Aguado C, Luna AM, Fern\u00e1ndez L, P\u00e9rez J, Font C, Salvador C, Corral J, Ben\u00edtez G, Ros S, Biosca M, Calvo V, Mart\u00ednez J, S\u00e1nchez-C\u00e1novas M, L\u00f3pez R, Sereno M, Mielgo X, Aparisi F, Carmona M, Carri\u00f3n R, Ponce-Aix S, Soares M, Mart\u00ednez-Salas I, Garc\u00eda-Morillo M, Juan-Vidal O, Blasco A, Mu\u00f1oz AJ, Paz-Ares L (2020) High risk of thrombosis in patients with advanced lung cancer harboring rearrangements in ROS1. Eur J Cancer 141:193\u2013198. https:\/\/doi.org\/10.1016\/j.ejca.2020.10.002","journal-title":"Eur J Cancer"},{"key":"3306_CR59","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.lungcan.2020.01.017","volume":"142","author":"M Alexander","year":"2020","unstructured":"Alexander M, Pavlakis N, John T, O\u2019Connell R, Kao S, Hughes BGM, Lee A, Hayes SA, Howell VM, Clarke SJ, Millward M, Burbury K, Solomon B, Itchins M (2020) A multicenter study of thromboembolic events among patients diagnosed with ROS1-rearranged non-small cell lung cancer. Lung Cancer 142:34\u201340. https:\/\/doi.org\/10.1016\/j.lungcan.2020.01.017","journal-title":"Lung Cancer"},{"issue":"1","key":"3306_CR60","doi-asserted-by":"publisher","first-page":"e006072","DOI":"10.1136\/jitc-2022-006072","volume":"11","author":"AA Khorana","year":"2023","unstructured":"Khorana AA, Palaia J, Rosenblatt L, Pisupati R, Huang N, Nguyen C, Barron J, Gallagher K, Bond TC (2023) Venous thromboembolism incidence and risk factors associated with immune checkpoint inhibitors among patients with advanced non-small cell lung cancer. J Immunother Cancer 11(1):e006072. https:\/\/doi.org\/10.1136\/jitc-2022-006072","journal-title":"J Immunother Cancer"},{"key":"3306_CR61","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1111\/jth.13378","volume":"14","author":"AS Mansfield","year":"2016","unstructured":"Mansfield AS, Tafur AJ, Wang CE, Kourelis TV, WysokinskaEM YP (2016) Predictors of active cancer thromboembolic outcomes: validation of the Khorana score among patients with lungcancer. J Thromb Haemost 14:1773\u20131778. https:\/\/doi.org\/10.1111\/jth.13378","journal-title":"J Thromb Haemost"},{"issue":"8","key":"3306_CR62","doi-asserted-by":"publisher","first-page":"1940","DOI":"10.1111\/jth.14824","volume":"18","author":"ES van Nick","year":"2020","unstructured":"van Nick ES, Ventresca M, Di Nisio M, Zhou Q, Noble S, Crowther M, Briel M, Garcia D, Lyman GH, Macbeth F, Griffiths G, Iorio A, Mbuagbaw L, Neumann I, Brozek J, Guyatt G, Streiff MB, Baldeh T, Florez ID, Gurunlu Alma O, Agnelli G, Ageno W, Marcucci M, Bozas G, Zulian G, Maraveyas A, Lebeau B, Lecumberri R, Sideras K, Loprinzi C, McBane R, Pelzer U, Riess H, Solh Z, Perry J, Kahale LA, Bossuyt PM, Klerk C, B\u00fcller HR, Akl EA, Sch\u00fcnemann HJ, IPDMA Heparin Use in Cancer Patients Research Group (2020) The Khorana score for prediction of venous thromboembolism in cancer patients: an individual patient data meta-analysis. J Thromb Haemost 18(8):1940\u20131951. https:\/\/doi.org\/10.1111\/jth.14824","journal-title":"J Thromb Haemost"},{"issue":"2","key":"3306_CR63","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1177\/1076029611433769","volume":"18","author":"SK Haas","year":"2012","unstructured":"Haas SK, Freund M, Heigener D, Heilmann L, Kemkes-Matthes B, von Tempelhoff GF, Melzer N, Kakkar AK, Investigators TOPIC (2012) Low-molecular-weight heparin versus placebo for the prevention of venous thromboembolism in metastatic breast cancer or stage III\/IV lung cancer. Clin Appl Thromb Hemost 18(2):159\u2013165. https:\/\/doi.org\/10.1177\/1076029611433769","journal-title":"Clin Appl Thromb Hemost"},{"issue":"5","key":"3306_CR64","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1200\/JCO.2015.64.0268","volume":"34","author":"F Macbeth","year":"2016","unstructured":"Macbeth F, Noble S, Evans J, Ahmed S, Cohen D, Hood K, Knoyle D, Linnane S, Longo M, Moore B, Woll PJ, Appel W, Dickson J, Ferry D, Brammer C, Griffiths G (2016) Randomized phase iii trial of standard therapy plus low molecular weight heparin in patients with lung cancer: FRAGMATIC Trial. J Clin Oncol 34(5):488\u2013494. https:\/\/doi.org\/10.1200\/JCO.2015.64.0268","journal-title":"J Clin Oncol"},{"key":"3306_CR65","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.thromres.2017.03.024","volume":"154","author":"HE Fuentes","year":"2017","unstructured":"Fuentes HE, Oramas DM, Paz LH, Casanegra AI, Mansfield AS, Tafur AJ (2017) Meta-analysis on anticoagulation and prevention of thrombosis and mortality among patients with lung cancer. Thromb Res 154:28\u201334. https:\/\/doi.org\/10.1016\/j.thromres.2017.03.024","journal-title":"Thromb Res"},{"issue":"1","key":"3306_CR66","doi-asserted-by":"publisher","first-page":"e062768","DOI":"10.1136\/bmjopen-2022-062768","volume":"13","author":"J T\u00f8nnesen","year":"2023","unstructured":"T\u00f8nnesen J, Pallisgaard J, Rasmussen PV, Ruwald MH, Lamberts M, Nouhravesh N, Strange J, Gislason GH, Hansen ML (2023) Risk and timing of venous thromboembolism in patients with gastrointestinal cancer: a nationwide Danish cohort study. BMJ Open 13(1):e062768. https:\/\/doi.org\/10.1136\/bmjopen-2022-062768","journal-title":"BMJ Open"},{"issue":"1","key":"3306_CR67","doi-asserted-by":"publisher","first-page":"18516","DOI":"10.1038\/s41598-020-75719-w","volume":"10","author":"H Abdel-Razeq","year":"2020","unstructured":"Abdel-Razeq H, Mustafa R, Sharaf B, Al-Tell A, Braik D, Ashouri K, Omari Z, Mansour R, Qarqash J, Shaqboua H, Jaradat S, Al-Qasem K, Bater R (2020) Patterns and predictors of thromboembolic events among patients with gastric cancer. Sci Rep 10(1):18516. https:\/\/doi.org\/10.1038\/s41598-020-75719-w","journal-title":"Sci Rep"},{"issue":"5","key":"3306_CR68","doi-asserted-by":"publisher","first-page":"e12549","DOI":"10.1002\/rth2.12549","volume":"5","author":"JV Mones","year":"2021","unstructured":"Mones JV, Streiff MB, Khorana AA, Bendheim GA, Damaraju CV, Wildgoose P, Burton P, Riess H, Soff GA (2021) Rivaroxaban thromboprophylaxis for gastric\/gastroesophageal junction tumors versus other tumors: a post hoc analysis of the randomized CASSINI trial. Res Pract Thromb Haemost 5(5):e12549. https:\/\/doi.org\/10.1002\/rth2.12549","journal-title":"Res Pract Thromb Haemost"},{"issue":"11","key":"3306_CR69","doi-asserted-by":"publisher","first-page":"1886","DOI":"10.1055\/s-0039-1695769","volume":"119","author":"S Miranda","year":"2019","unstructured":"Miranda S, Benhamou Y, Wells P, Carrier M (2019) Safety of primary thromboprophylaxis using apixaban in ambulatory cancer patients with intracranial metastatic disease or primary brain tumors. Thromb Haemost 119(11):1886\u20131887","journal-title":"Thromb Haemost"},{"issue":"9","key":"3306_CR70","doi-asserted-by":"publisher","first-page":"1959","DOI":"10.1111\/j.1538-7836.2010.03973.x","volume":"8","author":"KR Perry","year":"2010","unstructured":"Perry KR, Julian JA, Laperriere NJ, Geerts W, Agnelli G, Rogres LR et al (2010) PRODIGE: a randomized placebo-controlled trial of dalteparin low-molecular-weight heparin thromboprophylaxis in patients with newly diagnosed malignant glioma. J Thromb Haemost 8(9):1959\u20131965","journal-title":"J Thromb Haemost"},{"issue":"4","key":"3306_CR71","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1182\/blood-2015-02-626788","volume":"126","author":"J Donato","year":"2015","unstructured":"Donato J, Campigotto F, Uhlmann EJ, Coletti E, Neuberg D, Weber GF et al (2015) Intracranial hemorrhage in patients with brain metastases treated with therapeutic enoxaparin: a matched cohort study. Blood 126(4):494\u2013499. https:\/\/doi.org\/10.1182\/blood-2015-02-626788","journal-title":"Blood"},{"issue":"16","key":"3306_CR72","doi-asserted-by":"publisher","first-page":"4873","DOI":"10.1182\/bloodadvances.2022008086","volume":"6","author":"M Giustozzi","year":"2022","unstructured":"Giustozzi M, Proietti G, Becattini C, Roila F, Agnelli G, Mandal\u00e0 M (2022) ICH in primary or metastatic brain cancer patients with or without anticoagulant treatment: a systematic review and meta-analysis. Blood Adv 6(16):4873\u20134883. https:\/\/doi.org\/10.1182\/bloodadvances.2022008086","journal-title":"Blood Adv"},{"key":"3306_CR73","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.thromres.2020.10.026","volume":"197","author":"W Knoll","year":"2021","unstructured":"Knoll W, Mallick R, Wells PS, Carrier M (2021) Safety and efficacy of apixaban thromboprophylaxis in cancer patients with metastatic disease: A post-hoc analysis of the AVERT trial. Thromb Res 197:13\u201315. https:\/\/doi.org\/10.1016\/j.thromres.2020.10.026","journal-title":"Thromb Res"},{"key":"3306_CR74","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s11739-018-1956-1","volume":"14","author":"D Prisco","year":"2019","unstructured":"Prisco D, Tufano A, Cenci C, Pignatelli P, Santilli F, Di Minno G, Perticone F (2019) Position paper of the Italian Society of Internal Medicine (SIMI) on prophylaxis and treatment of venous thromboembolism in patients with cancer. Intern Emerg Med 14:21\u201338. https:\/\/doi.org\/10.1007\/s11739-018-1956-1","journal-title":"Intern Emerg Med"},{"issue":"8","key":"3306_CR75","doi-asserted-by":"publisher","first-page":"1852","DOI":"10.1111\/jth.15354","volume":"19","author":"N Watson","year":"2021","unstructured":"Watson N, Al-Samkari H (2021) Thrombotic and bleeding risk of angiogenesis inhibitors in patients with and without malignancy. J Thromb Haemost 19(8):1852\u20131863. https:\/\/doi.org\/10.1111\/jth.15354","journal-title":"J Thromb Haemost"},{"key":"3306_CR76","unstructured":"Sanfilippo K, Luo S, Khorana A, Gage B (2021) Three Available Risk Scores Modestly Predict Hemorrhage in Patients with Cancer-associated Thrombosis (CAT) [abstract]. Res Pract Thromb Haemost 5 (Suppl 2). https:\/\/abstracts.isth.org\/abstract\/three-available-risk-scores-modestly-predict-hemorrhage-in-patients-with-cancer-associated-thrombosis-cat\/. Accessed 12 Nov 2022"},{"issue":"7","key":"3306_CR77","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1056\/NEJMoa1711948","volume":"378","author":"GE Raskob","year":"2018","unstructured":"Raskob GE, van Nick ES, Verhamme P, Carrier M, Di Nisio M, Garcia D, Grosso MA, Kakkar AK, Kovacs MJ, Mercuri MF, Meyer G, Segers A, Shi M, Wang TF, Yeo E, Zhang G, Zwicker JI, Weitz JI, B\u00fcller HR, Hokusai VTE Cancer Investigators (2018) Edoxaban for the treatment of cancer-associated venous thromboembolism. N Engl J Med 378(7):615\u2013624. https:\/\/doi.org\/10.1056\/NEJMoa1711948","journal-title":"N Engl J Med"},{"issue":"16_suppl","key":"3306_CR78","doi-asserted-by":"publisher","first-page":"e18744","DOI":"10.1200\/JCO.2022.40.16_suppl.e18744","volume":"40","author":"AJ Mu\u00f1oz Mart\u00edn","year":"2022","unstructured":"Mu\u00f1oz Mart\u00edn AJ, Palacios ML, Souto JC, Obispo B, Aparicio J, Garc\u00eda-Palomo A et al (2022) Predicting major bleeding events in anticoagulated cancer patients with venous thromboembolism using real-world data and machine learning. JCO 40(16_suppl):e18744\u2013e18744. https:\/\/doi.org\/10.1200\/JCO.2022.40.16_suppl.e18744","journal-title":"JCO"},{"issue":"4","key":"3306_CR79","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1007\/s12094-020-02472-x","volume":"23","author":"J Mu\u00f1oz-Langa","year":"2021","unstructured":"Mu\u00f1oz-Langa J, Jimenez-Fonseca P, Carmona-Bayonas A, de Castro EM, P\u00e9rez-Segura P, C\u00e1novas MS, Gomez D, Moran LO, de Tejada MBG, Segu\u00ed E, L\u00f3pez GB, Adri\u00e1n SG, Campos MC, Olmos VP, Portero BO, Moyano MS, Crespo JAS, S\u00e1nchez LT, Rebollo MA, Rivas PO, Altozano JP, Lescure \u00c1R, Mu\u00f1oz-Mart\u00edn A (2021) Rationale, design and methodology of TESEO study: a registry of thrombosis and neoplasia of SEOM (Spanish Society of Medical Oncology). Clin Transl Oncol 23(4):799\u2013811. https:\/\/doi.org\/10.1007\/s12094-020-02472-x","journal-title":"Clin Transl Oncol"},{"issue":"5","key":"3306_CR80","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1160\/TH08-05-0339","volume":"100","author":"J Trujillo-Santos","year":"2008","unstructured":"Trujillo-Santos J, Di Micco P, Iannuzzo M, Lecumberri R, Guijarro R, Madridano O, Monreal M, RIETE Investigators (2008) Elevated white blood cell count and outcome in cancer patients with venous thromboembolism findings from the RIETE registry. Thromb Haemost 100(5):905\u2013911","journal-title":"Thromb Haemost"}],"container-title":["Internal and Emergency Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11739-023-03306-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11739-023-03306-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11739-023-03306-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,15]],"date-time":"2023-09-15T08:26:07Z","timestamp":1694766367000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11739-023-03306-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,25]]},"references-count":80,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["3306"],"URL":"https:\/\/doi.org\/10.1007\/s11739-023-03306-8","relation":{},"ISSN":["1828-0447","1970-9366"],"issn-type":[{"type":"print","value":"1828-0447"},{"type":"electronic","value":"1970-9366"}],"subject":[],"published":{"date-parts":[[2023,5,25]]},"assertion":[{"value":"11 March 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 May 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 May 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Human and animal rights statement and Informed consent is not applicable to this review.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and animal rights statement and Informed consen"}},{"value":"MV declare no competing financial interests. AM reports lecture fees from Sanofi, Celgene, MBS-Pfizer, Leo Pharma, Daiichi Sanchyo, Incyte, AstraZeneca, MSD, Lilly, Roche, Rovi, Servier, Bayer, Menarini and STADA and research funding to the Institution by Sanofi, Leo-pharma e Colgene. J. C. reports lecture fees and consultancies for Roche, Sanofi and Abbott and research funding to the Institution by CLS behring outside the submitted paper. \nThis research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"conflict of interest"}}]}}